News & Updates

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Patients with inflammatory bowel disease (IBD) who consume probiotics can develop brain fog, especially men and those who are Caucasian, as suggested in a study.